1 active not recruiting. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Active not recruiting 1 |
Follow Bruce Cree: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis KYV-101 (Biological) - 0.33 ×10^8 cells, KYV-101 (Biological) - 1 ×10^8 cells, Chemotherapy: cyclophosphamide (CYC) - Progressive Multiple Sclerosis | Phase 1 | Active not recruiting | Bruce Cree | 10 | 2024-06-20 | 2026-08-10 |
Multiple Sclerosis (1) · Multiple Sclerosis, Chronic Progressive (1)
Biological Products (1) · Immunotherapy, Adoptive (1)
United States (1)
Sasha Gupta, MD (1)